This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

SB-509

Sangamo Biosciences, Inc.

Drug Names(s): EW-A-401, ZFP Therapeutic, VEGF activator zinc finger protein

Description: SB-509 is an injectable formulation of plasmid DNA that encodes a zinc finger DNA-binding protein transcription factor (ZFP TFTM), designed to upregulate the vascular endothelial growth factor A (VEGF-A) gene.

VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties. In preclinical animal efficacy studies in a diabetic rat model, SB-509 has proven effective in protecting motor and sensory nerve function from disease-induced nerve damage.

Deal Structure: In December 2006, Edwards Lifesciences and Sangamo BioSciences entered into a definitive asset purchase agreement under which Sangamo acquired Edwards' angiogenesis program. Sangamo acquired two clinical stage programs in peripheral vascular disease (PAD) and a late stage pre-clinical program in ischemic heart disease (IHD).


SB-509 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug